Frontier Capital Management’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
Other funds holding KYMR
BBA
Frontier Capital Management's KYMR Position: Q3 2026 in Review
Frontier Capital Management reduced its Kymera Therapeutics (KYMR) stake by 24% in Q3 2026, selling an estimated $20.2M and leaving 564,133 shares worth $63.1M. The position accounts for 0.67% of the portfolio, ranked #41.
Frontier Capital Management first reported a position in KYMR in Q3 2024 and has held it in 9 quarters since. The position peaked at $85M in Q2 2026. 301 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.
- Frontier Capital Management held 564,133 shares of Kymera Therapeutics worth $63.1M as of Q3 2026.
- Frontier Capital Management sold 176,733 Kymera Therapeutics shares in Q3 2026, an estimated $20.2M.
- Kymera Therapeutics made up 0.67% of Frontier Capital Management's portfolio in Q3 2026, its #41 holding.
- Frontier Capital Management first reported a position in Kymera Therapeutics in Q3 2024 and has held it in 9 quarters since.
- Frontier Capital Management's Kymera Therapeutics position peaked at $85M in Q2 2026.
- 301 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.
Based on Frontier Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.